MoonLake Immunotherapeutics (MLTX)
40.86
+0.17
(+0.42%)
USD |
NASDAQ |
May 16, 16:00
40.85
-0.01
(-0.02%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value: 2.032B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 2.032B |
| May 15, 2024 | 2.021B |
| May 14, 2024 | 2.026B |
| May 13, 2024 | 2.085B |
| May 10, 2024 | 2.036B |
| May 09, 2024 | 2.102B |
| May 08, 2024 | 2.143B |
| May 07, 2024 | 2.208B |
| May 06, 2024 | 2.262B |
| May 03, 2024 | 2.308B |
| May 02, 2024 | 2.139B |
| May 01, 2024 | 2.156B |
| April 30, 2024 | 2.035B |
| April 29, 2024 | 2.089B |
| April 26, 2024 | 2.134B |
| April 25, 2024 | 2.119B |
| April 24, 2024 | 2.131B |
| April 23, 2024 | 2.182B |
| April 22, 2024 | 2.042B |
| April 19, 2024 | 2.115B |
| April 18, 2024 | 2.119B |
| April 17, 2024 | 2.198B |
| April 16, 2024 | 2.198B |
| April 15, 2024 | 2.207B |
| April 12, 2024 | 2.224B |
| Date | Value |
|---|---|
| April 11, 2024 | 2.333B |
| April 10, 2024 | 2.366B |
| April 09, 2024 | 2.402B |
| April 08, 2024 | 2.372B |
| April 05, 2024 | 2.429B |
| April 04, 2024 | 2.354B |
| April 03, 2024 | 2.353B |
| April 02, 2024 | 2.434B |
| April 01, 2024 | 2.518B |
| March 28, 2024 | 2.665B |
| March 27, 2024 | 2.664B |
| March 26, 2024 | 2.656B |
| March 25, 2024 | 2.760B |
| March 22, 2024 | 2.776B |
| March 21, 2024 | 2.800B |
| March 20, 2024 | 2.619B |
| March 19, 2024 | 2.688B |
| March 18, 2024 | 2.560B |
| March 15, 2024 | 2.478B |
| March 14, 2024 | 2.259B |
| March 13, 2024 | 2.330B |
| March 12, 2024 | 2.402B |
| March 11, 2024 | 2.465B |
| March 08, 2024 | 2.375B |
| March 07, 2024 | 2.373B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
132.19M
Minimum
Jun 30 2022
3.368B
Maximum
Feb 12 2024
1.342B
Average
904.86M
Median
Apr 18 2023
Enterprise Value Benchmarks
| Qiagen NV | 10.81B |
| LENZ Therapeutics Inc | 208.81M |
| AC Immune SA | 221.07M |
| CRISPR Therapeutics AG | 2.619B |
| Addex Therapeutics Ltd | 4.792M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.67M |
| Total Expenses (Quarterly) | 19.82M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -1.79% |